Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Roche Holding AG (OTCQX International Premier:RHHVF)

260.07
Delayed Data
As of Jun 27
 +1.50 / +0.58%
Today’s Change
216.45
Today|||52-Week Range
276.80
+14.09%
Year-to-Date
Roche's (RHHBY) Combination Cancer Remedy Wins FDA Approval
Jun 26 / Zacks.com - Paid Partner Content
Novartis (NVS) Biosimilar of MabThera Approved in the EU
Jun 19 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk
Jun 26 / Zacks.com - Paid Partner Content
Celgene Presents Interim Results from Cancer Drug Study
Jun 19 / Zacks.com - Paid Partner Content
Allergan Continues to Focus on Acquisitions and Branded Unit
Jun 26 / Zacks.com - Paid Partner Content
Does Roche Holding (RHHBY) Look to be a Great Value Pick?
Jun 19 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod
Jun 23 / Zacks.com - Paid Partner Content
J&J Immunotherapy Darzalex Ok'd for Expanded Combination Use
Jun 19 / Zacks.com - Paid Partner Content
Seeking Value in Biotech: Biogen
Jun 22 / GuruFocus News - Paid Partner Content
Here's Why Clovis (CLVS) Stock is Up Almost 350% in One Year
Jun 16 / Zacks.com - Paid Partner Content
Novartis Announces Positive Results for Cardiovascular Drug
Jun 22 / Zacks.com - Paid Partner Content
Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval
Jun 15 / Zacks.com - Paid Partner Content
Exelixis's Cabometyx Positive for First-Line Kidney Cancer
Jun 20 / Zacks.com - Paid Partner Content
Why is Alnylam's (ALNY) Stock Close to 100% this Year?
Jun 15 / Zacks.com - Paid Partner Content
Clovis Up Nearly 50% on Solid Data from Ovarian Cancer Study
Jun 20 / Zacks.com - Paid Partner Content
Epizyme Provides Positive Interim Data on EZH2 Inhibitor
Jun 15 / Zacks.com - Paid Partner Content